These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

277 related items for PubMed ID: 24164102

  • 1. Dosing related effects of zoledronic acid on bone markers and creatinine clearance in patients with multiple myeloma and metastatic breast cancer.
    Søe K, Delaissé JM, Jakobsen EH, Hansen CT, Plesner T.
    Acta Oncol; 2014 Apr; 53(4):547-56. PubMed ID: 24164102
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Efficacy and safety of zoledronic acid in patients with breast cancer metastatic to bone: a multicenter clinical trial.
    Cartenì G, Bordonaro R, Giotta F, Lorusso V, Scalone S, Vinaccia V, Rondena R, Amadori D.
    Oncologist; 2006 Apr; 11(7):841-8. PubMed ID: 16880243
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomised open-label phase 3 trial.
    Coleman R, Cameron D, Dodwell D, Bell R, Wilson C, Rathbone E, Keane M, Gil M, Burkinshaw R, Grieve R, Barrett-Lee P, Ritchie D, Liversedge V, Hinsley S, Marshall H, AZURE investigators.
    Lancet Oncol; 2014 Aug; 15(9):997-1006. PubMed ID: 25035292
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Synergistic inhibitory activity of zoledronate and paclitaxel on bone metastasis in nude mice.
    Lu S, Zhang J, Zhou Z, Liao ML, He WZ, Zhou XY, Li ZM, Xiang JQ, Wang JJ, Chen HQ.
    Oncol Rep; 2008 Sep; 20(3):581-7. PubMed ID: 18695909
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Zoledronic acid improves clinical outcomes in patients with bone metastatic hormone-naïve prostate cancer in a multicenter clinical trial.
    Okegawa T, Higaki M, Matsumoto T, Kase H, Murata A, Noda K, Noda H, Asaoka H, Oshi M, Tomoishi J, Uchida H, Higashihara E, Nutahara K, Bone Metastasis Prostate Cancer Group.
    Anticancer Res; 2014 Aug; 34(8):4415-20. PubMed ID: 25075079
    [Abstract] [Full Text] [Related]

  • 14. Evaluation of the clinical benefit of long-term (beyond 2 years) treatment of skeletal-related events in advanced cancers with zoledronic acid.
    Henk H, Teitelbaum A, Kaura S.
    Curr Med Res Opin; 2012 Jul; 28(7):1119-27. PubMed ID: 22536885
    [Abstract] [Full Text] [Related]

  • 15. Zoledronic acid: multiplicity of use across the cancer continuum.
    Lipton A.
    Expert Rev Anticancer Ther; 2011 Jul; 11(7):999-1012. PubMed ID: 21806323
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Zoledronic acid treatment at home: safety data from an observational prospective trial.
    Tassinari D, Poggi B, Nicoletti S, Fantini M, Tamburini E, Possenti C, Sartori S.
    J Palliat Med; 2007 Apr; 10(2):352-8. PubMed ID: 17472506
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.